Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

By Nikita Chaurasia  Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Netflix confirms producing fictionalized version of Spotify’s ascension

Netflix confirms producing fictionalized version of Spotify’s ascension

By Nikita Chaurasia

Over-the-top content streaming & production giant Netflix Inc. is reportedly working on an untitled series that tells the story of one of the most successful music streaming companies, Spotify Ltd. The six-part series, already listed on Netflix,...

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

By Nikita Chaurasia

Byju’s, the largest education technology company, has emerged as India’s highest-valued startup after a USD 340 million funding round involving investors such as UBS Group, Blackstone, and Zoom founder Eric Yuan among others. Recently, B...

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

By Nikita Chaurasia

Hesai Photonics Technology Co. Ltd., a leading Shanghai-based LiDAR company, has reportedly secured USD 300 million in a Series D funding round which was led by GL Ventures LLC, Xiaomi Corporation, Hillhouse Capital Group, Meituan, and CPE. The roun...

Tesla terminates production of its Model S Plaid + variant indefinitely

Tesla terminates production of its Model S Plaid + variant indefinitely

By Nikita Chaurasia

CEO Elon Musk justified Model S Plaid as good enough against its successor. The Model S Plaid + was touted to be Tesla’s flagship vehicle, with a range of around 519 miles. After unveiling for the first time last year, American EV maker T...

ByHeart concludes largest U.S. clinical trial for infant food product

ByHeart concludes largest U.S. clinical trial for infant food product

By Nikita Chaurasia

ByHeart Inc., a New-York based infant, and baby nutrition company, has recently announced the completion of the largest clinical trial for new infant formula in the past 25 years. With this move, the company is earmarked to be the 4th FDA registered,...